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Poor Prognosis in Multiple Myeloma Is Associated Only With Partial or Complete Deletions of Chromosome 13 or Abnormalities Involving l l q and Not With Other Karyotype Abnormalities
By Guido Tricot, Bart Barlogie, Sundar Jagannath, Dwayne Bracy, Sandy Mattox, David H. Vesole, Sally Naucke, and Jeffery R. Sawyer
Chromosomal abnormalities have major biologic and prognostic implications in leukemias. Cytogenetic information in typically hypoproliferative multiple myeloma (MM) is limited because of difficulties in obtaining analyzable metaphases. In this study, karyotypes and other known prognostic factors were analyzed in 155 newly diagnosed MM patients, entered on an intensive treatment program with two autotransplants. Complete remission (CR), event-free (EFS) and overall survival (OS) were analyzed using standard statistical methods. Abnormal Cytogenetics were found in 39% of patients and were associated with a significantly lower CR rate (2790 v48Y0; P = .008). EFS and OS were inferior in patients with either partial or complete deletion of chromosome 13 or 1 Iq abnormalities ("unfavorable" karyotype) when compared with the remaining patients ( P < .001) who, as a group, had a similar prognosis irrespective of cytogenetic findings, ie, inevaluable, normal, or abnormal but without an "unfavorable" karyotype. The patients with abnormalities of both chromosomes 11 and 13 had a dismal prognosis with ULTIPLE MYELOMA (MM) is a prototype of a clonal B-cell tumor with monoclonal protein production in more than 90% of patients. Survival ranges from a few months to many years with a median of 3 years.' B2M, C-reactive protein (CRP), and the plasma cell labeling index (PCLI) are considered the best prognostic indicators for survival. 2, 3 The search for more biologically relevant prognostic factors continues, in order to guide therapy and identify novel interventions based on well defined genetic anomalies. While no single genetic lesion has been identified in MM, a range of different oncogene and suppressor gene abnormalities has been described, including c -r n~c ,~ r a~, ' .~ bcl-2,' Rb-18,9 and ~5 3 .~. "
Rb-l and p53 both repress interleukin-6 (IL-6)," a putative growth factor in MM"; p53 also inhibits expression of b~l -2 , '~ a well-known antiapoptosis factor in B-cell malignancies including ".l4 Cytogenetic studies have major prognostic importance in leukemia^.'^,'^ Unfortunately, because of difficulties in obtaining analyzable metaphases, cytogenetic information is median EFS and OS of only 11 and 12 months, respectively. Significant associations were noted between an "unfavorable" karyotype and IgA isotype, elevated levels of beta-2 microglobulin WM. 23 mg/L) and age >60 years. On multivariate regression analysis, the absence of an "unfavorable" karyotype was the most significant variable associated with prolonged EFS and OS (P = .OW1 and .OW& respectively).
Other independent favorable variables were age less than 60 years, C-reactive protein (CRP) 50.4 mg/dL and bone marrow plasmacytosis 550% before treatment. On a multivariate analysis without cytogenetics, these same three standard parameters were identified as the only favorable variables. Patients not having all three standard favorable variables had a significantly lower CR rate (P = .03), EFS (P = .WO1), and OS ( P = .W21 if an unfavorable karyotype was detected. We conclude that, in this program of uniformly treated MM patients, a poor prognosis was associated predominantly with abnormalities of chromosomes 11 and 13. limited in MM, a malignancy composed mainly of terminally differentiated B cells with low proliferative activity. Flow cytometric analysis of nuclear DNA content of Gl Io cells, however, has demonstrated aneuploidy in 80% of patients,' in contrast to abnormal karyotypes observed in only 30% to 45% of case^.'^-^^ Typically, previously treated and relapsing patients have a higher frequency of chromosome abnormalities (35% to 60%), compared with those with newly diagnosed disease (18% to 35%).I7-'O Based on flow cytometryderived aneuploidy data, it is likely that the majority of normal karyotypes in MM are derived from normal hematopoietic cells.
The higher incidence of abnormal cytogenetics in advanced myeloma probably reflects an increased proliferative rate with disease progression." It is, therefore, not surprising that in studies combining newly diagnosed and previously treated patients, abnormal cytogenetics are associated with a significantly inferior o~t c o m e . '~. '~ However, a poor outcome of newly diagnosed MM patients with abnormal cytogenetics has been reported in only two relatively small studnever been linked to specific chromosomal aberrations.
We have analyzed cytogenetic data in 155 recently diagnosed MM patients (105, no prior therapy; 50, one cycle of prior therapy) who were entered on an intensive treatment protocol, including high-dose cyclophosphamide for peripheral stem cell mobilization followed by two autotransplants. Abnormal cytogenetics were found in 39% of patients. Partial or complete deletion of chromosome 13 andor 1 Iq abnormalities were associated with a significantly inferior outcome, while patients with other cytogenetic anomalies fared equally well as those with normal or inevaluable karyotypes.
On multivariate regression analysis, the absence of an unfavorable karyotype, as defined above, was the single most important parameter associated with prolonged event-free (EFS) and overall survival (OS). 
MATERIALS AND METHODS
Between August 22, 1990 , and March 1, 1994, 178 patients were entered on the "Total Therapy" protocol, designed to increase the frequency and duration of true complete remission (CR), as defined below, by using noncross-resistant induction regimens (VAD [vincristine, adriamycin, dexamethasone] X 2 or 3; cyclophosphamide 6 g/m2 with subsequent blood and bone marrow collection and one course of EDAP: etoposide, dexamethasone, cytarabine, and cisplatin), followed by two autotransplants within 3 to 6 months, using melphalan 200 mg/mz for the first transplant and again for the second if at least partial response (PR), as defined below, was attained; otherwise, melphalan 140 mg/mz and total body irradiation (TBI) 850 to 1,125 cGy was given in case of less than PR. Maintenance therapy employed a-interferon until disease recurrence. 22 Of the 178 patients, two had no cytogenetic analysis performed, and a further 21 cases were excluded because CRP values before treatment were unavailable. Of the remaining 155 patients-the subjects of this study-60 had at least one abnormal and 79 at least two normal karyotypes before their first transplant. Sixteen patients were classified as having inevaluable cytogenetics, because they had insufficient metaphases (N = 3) or only one normal karyotype (N = 12). The frequency of karyotype analyses was one in 12%, two in 22%, three in 17%, four in 21%, and at least five in 28% of cases.
Relevant patient characteristics are listed in Table 1 . Of the 155 patients, 97% completed VAD, 94% high-dose cyclophosphamide, 88% EDAP, 87% the first and 71% the second autotransplant. In accordance with institutional guidelines, patients were required to sign an informed consent, delineating potential risks and benefits associated with the treatment.
Sensitive disease before transplantation was defined as 250% reduction in serum and/or urine M protein after VAD chemotherapy. PR required tumor mass reduction by at least 75% and reduction in Bence Jones proteinuria to less than 100 mg/day; bone marrow aspirate and biopsy could not contain more than 5% plasma cells. A CR was defined by the absence of monoclonal gammopathy in serum and urine using immunofixation analysis in addition to a normal bone marrow aspirate and biopsy. With both PR and CR. these findings had to be present on at least two occasions with a minimum interval of 2 months. New lytic lesions, hypercalcemia, or other disease manifestations constituted relapse or progressive disease.
EFS and OS both were calculated from the time of entering the study. Events included disease relapse or progression and death from any cause. In case of survival projections, deaths from disease or other causes were considered as events.
Cytogenetic analysis was performed on bone marrow samples by standard techniques. A direct harvest, a 24-hour unsynchronized and a 48-hour synchronized culture were employed on most specimens. The 24-hour culture employed the addition of ethidium bromide (10 pg/mL) to the culture 2 hours before the harvest with an additional 1 hour colcemid (0.05 pgImL). The 48-hour synchronized cultures employed a 17-hour exposure of cells to IO" methotrexate. No cytokines or CD40 ligand were added to the cultures. Cells were washed with one change of unsupplemented media and then released with thymidine. Colcemid (0.05 pg/mL) was added 5 hours later for a period of 1 hour. At least 20 metaphases were analyzed. An abnormal clone was identified as two or more metaphases with either the same structural abnormality or the same extra chromosome or at least three cells with the same missing chromosome. Aberrations were designated according to ISCN (1991) ."
The following variables were analyzed at study entry in all patients: B2M, CRP, age, stage according to Dune-Salmon, hemoglobin, creatinine, LDH, albumin, percent marrow plasmacytosis, and Ig isotype. Statistical methods included Kaplan-Meier estimates of EFS and OS using a landmark technique to allow for the time interval required to have multiple karyotypes performed (6 months). EFS and OS were compared using log rank analysis. By using a 6-month landmark analysis, 149 patients were evaluable for EFS and OS. Multivariate regression analysis was used to determine which of the variables, recognized on univariate analysis, retained independent significance.
RESULTS

Cytogenetic Findings
Sixty of 155 patients (39%) had an abnormal karyotype. A cytogenetic anomaly was detected on the first attempt in 71%, with an additional 15% and 14% with the second and third examination, respectively. Because there was no significant difference in EFS ( P = .2) or OS (P = .9) seen in patients in whom an abnormal karyotype was detected with the first versus a subsequent karyotype analysis, all patients with an abnormal karyotype were analyzed together.
The most common karyotype anomalies are listed in Table  2 . Sixteen patients had a complete loss of chromosome 13 (two had nullisomy 13), five had a partial deletion of the long arm of chromosome 13 with the breakpoint at q12-14 and one had a combined monosomy 13 and 13q-. Eight patients with l l q abnormalities had t(l1; 14)(q11-13; ¶32), two had a deletion 1 l q (q13 in one and q21 in one), one t(8; ll)(p21;q12), one t(9; ll)(q34;q12), one t(l1; 12) (q23;qll) and one addition llq24. The incidence of -13/ 13q-and/or l l q abnormality was 16% in patients less than 60 years, compared with 32% in those 2 6 0 years ( P = .03). IgA myeloma was significantly more frequent in patients with an "unfavorable" karyotype (-13/13q-and/or I l q abnormality) (32% v 10%; P = .001), as was B2M >3.0 mg/ L ( P = .Ol). Abnormal cytogenetics were independent of the extent of bone marrow plasmacytosis ( P = .7).
Prognostic Signifzcance of the Cytogenetic Findings
Patients with an abnormal karyotype had a significantly lower CR rate (27% v 48%; P = .008) as had those 2 6 0 years (12% v 48%; P = .0003) ( Table 3 ). The median followup of alive patients was 28 months (range, 10 to 53 months). Abnormal cytogenetics also were associated with an inferior EFS ( P = .009), while the difference in OS was almost significant ( P = .06). The worst prognosis was noted in patients with -13/13q-or 1 lq abnormality ("unfavorable" cytogenetics) ( P < .001). Significantly superior EFS and OS were observed among the three remaining patient groups, regardless whether they had normal or inevaluable cytogenetics or karyotype anomalies excluding 1 lq abnormalities and chromosome 13 deletions (Fig 1) . Figure 2 depicts EFS and OS for patients with either one or both of the "unfavorable" cytogenetic abnormalities and for the remaining subjects. EFS and OS was shortest for patients exhibiting both "unfavorable" chromosomal anomalies, intermediate with one of these "unfavorable" features, and longest in the remaining group with no "unfavorable" karyotype. Patients with chromosome abnormalities of l p ( P = .002), 14q ( P = .004), 6q ( P = .Ol), and lq ( P = .02) had shorter EFS than those with normal cytogenetics. A shorter OS, however, was observed only for patients with lp ( P = .01) and 14q abnormalities ( P = .03). After removing patients with "unfavorable" karyotypes, none of these chromosome abnormalities per se was associated with an inferior outcome ( P > .2). The 23 patients, who were excluded from the analysis because of lack of cytogenetic information or CRP values, had a CR rate ( P = . l ) and durations of EFS ( P = .9) and OS ( P = .6) comparable to the 155 cases included in this study. In addition to an "unfavorable" karyotype, increasing age, bone marrow plasmacytosis, and CRP levels all affected EFS and OS adversely ( Table 3) . On multivariate regression analysis, the absence of an "unfavorable" karyotype was the most significant favorable parameter for EFS ( P = ,0001) and OS ( P = .0002). Other favorable variables for EFS and OS were age <60, CRP 50.4 mg/dL, and bone marrow plasmacytosis 550% before treatment ( Table 4 ).
An additional multivariate analysis for EFS and OS was performed without cytogenetics. Age <60 years ( P = .0001 and .0005), 550% bone marrow plasmacytosis ( P = .003 and .Ol), and CRP 50.4 mg/dL ( P = ,006 and .02) were identified as the only significantly favorable parameters. The 48 patients with all three of these favorable variables had comparable CR rate, EFS, and OS whether they had "unfavorable" cytogenetics (N = 5) or not (N = 43) . In contrast, a significantly lower CR rate ( P = .03) and shorter durations of EFS ( P = .0001) and OS ( P = .002) were observed in the 101 patients with less than three standard favorable variables if an "unfavorable" karyotype was present (N = 26) ( Table 5 ).
DISCUSSION
Almost 40% of recently diagnosed MM patients had an abnormal karyotype, usually detected with the first cytogenetic analysis (71%). The slightly higher frequency of abnormal karyotypes in our patients when compared with previous reports may be related to our referral pattern. Because patients are referred to our center for transplantation, we may see more patients with aggressive disease. Although it is possible that some patients have myeloma cells with a normal karyotype, conventional cytogenetics still fails to detect at least 40% of abnormal cytogenetics based on DNA aneuploidy data.' It can be assumed that karyotype anomalies occur early in MM based on the presence of DNA aneup l o i d~*~ and cytogenetic abnormalities2s already present in patients with monoclonal gammopathies of undetermined significance. The complexity of most MM karyotypes is consistent with a long subclinical course during which multiple aberrations have occurred. The distribution of karyotype anomalies in this study was comparable to our earlier report'" ( Table 2) . A significantly lower CR rate in patients with abnormal cytogenetics (27% v 48%; P = .OOS) suggests that an abnormal karyotype may be associated with the development of drug resistance, which can be overcome only partially even with high-dose chemotherapy and autotransplant support. Only partial or complete deletions of chromosome 13 or 1 lq abnormalities and not the other abnormal karyotypes were associated with an unfavorable EFS and OS when compared with patients with normal cytogenetics, suggesting that the genetic changes caused by these specific chromosome changes are directly responsible for the poor response to intensive therapy, and that abnormal karyotypes are not just an expression of major DNA damage. An unfavorable karyotype was associated with a significantly higher incidence of IgA myeloma, elevated B2M, and advanced age. All these variables have also been associated independently with a poor prognosis. 26 The inferior EFS and OS associated with IgA MM even with two autotransplants may be explained partially by the high incidence of unfavorable karyotypes. In an earlier analysis, chromosome 13 deletions and 14q abnormalities were associated with a poor prognosi~.~' Although patients with 14q abnormalities still had a significantly inferior EFS ( P = .02) in the current analysis, their poor prognosis was entirely due to cases with t( 11; 14). Patients with other 14q abnormalities had EFS (P = .9) and OS ( P = .3) comparable to those with normal cytogenetics, while those with 1 lq abnormalities other than t( 11; 14) actually had an EFS inferior to those with t( 1 l; 14) ( P = .02).
As our findings were obtained in patients undergoing intensive treatment with two autotransplants, other chromosome abnormalities might also confer a poor prognosis when standard therapy is employed. However, their negative impact, if present, can be overcome with increasing dose intensity.
The poor prognosis in patients with 1 lq abnormalities may be related to abnormalities of bcl-I expression, well documented in patients with t(l1; 14)(q13;q32).28 As a result of this translocation, bcl-l on chromosome 11 is juxtaposed to an IgHenhancer sequence located on chromosome 14. A gene located 110 kb telomeric of the bcl-l major translocation cluster region has been cloned and was found to be a member of the cyclin gene family, designated cyclin Dl. This gene is expressed in a wide range of human tissues, but is not normally expressed in cells of lymphoid or myeloid lineage^?^ Cyclin Dl stimulates phosphorylation of the Rb protein and thereby inactivates its growth-suppressive properties.3o Its overexpression does not only result from translocation, but also from gene amplification in various kinds of cancers with l l q abnormalities, such as esophageal, breast and bladder cancers, and squamous cell carcinomas of head and neck. bcl-l overexpression is associated with a poor prognosis in mantle cell lymphoma,"' splenic lymphoma with villous lympho~ytes~~ and lymphoplasmacytic lymph~ma.~' It is less clear why deletions of the long arm of chromosome 13 are associated with a poor prognosis. It is tempting to speculate that the inferior outcome in these patients is associated with a deletion of the Rb-l gene. The Rb protein plays a central role in the control of cell division.33 Underphosphorylated Rb protein predominates in G1 and phosphorylation by cyclin-dependent kinases relieves the G1 block and permits entry into S phase. Defective or absent Rb protein is, therefore, advantageous for cell proliferation and may initiate or contribute to the progression of cancer.
We have found deletion of the Rb-l gene in more than 50% of MM patients8 Loss of Rb protein was observed in 35% of primary cases of MM and plasma cell leukemia,' and inactivation of the Rb-l gene was associated with more aggressive disease. ' In primary lung cancer, a model of tumorigenesis has been proposed in which overexpression of cyclin Dl is an early event, followed by Rb protein It is, therefore, conceivuse only. able that the particularly dismal outcome of patients with abnormalities of both chromosomes 11 and 13 is related to increased phosphorylation of decreased amounts of Rb protein, conferring further loss of growth control. Although the Rb-l gene has been considered the most likely target of allelic deletions on 13q, most of the epithelial ovarian carcinomas with chromosome 13 deletions showed a normal Rb protein expression."s36 These studies, however, found a strong association between chromosome 13 deletions and a high-grade carcinoma phenotype with invasive and metastatic properties,"~~~ suggesting the presence of another tumor suppressor gene on chromosome 13 and an ' 'innocent bystander role" of the Rb-l gene deletion. A region located telomeric to the Rb-l gene has been identified, which is probably homozygously deleted in chronic lymphocytic leu- kemia (CLL),'7 another B-cell lymphoproliferative disease with a high frequency of monoallelic Rb-l deletions." The outcome of patients with multiple trisomies, mainly of odd chromosomes, was similar to that of cases with normal chromosomes. It may well be that the DNA damage, occurring in those patients, is partially offset by increased expression of suppressor genes, located on chromosomes 3 (VHL and MLHl), 5 (APC), 9 (MTS1) and 11 (WTl). 39 In conclusion, the presence of a partial or total deletion of chromosome 13 or l lq abnormalities was the most significant unfavorable variable for EFS and OS on multivariate regression analysis in recently diagnosed MM patients, treated with intensive approaches and was more significant than CRP, age, bone marrow plasmacytosis, disease stage, creatinine, H b , B2M, and albumin level. Using only standard prognostic factors, age <60 years, bone marrow plasmacytosis s50%, and CRP 50.4 mg/dL were found to be significant favorable varables. In patients lacking one or more of these three favorable features (68%), the presence of an unfavorable karyotype resulted in significantly inferior CR rate, EFS, and OS (Table  5) . Such difference was not observed in cases having all three favorable variables (32%), suggesting that the negative impact of an unfavorable karyotype can be offset by the presence of multiple standard favorable variables, the genetic basis for which is presently unknown. PCLIs were not performed in this study. Although it may be argued that an abnormal karyotype in MM is an expression of a hyperproliferative disease, it is unlikely that PCLI and cytogenetic findings confer the same biologic consequences. If that was the case, the finding of just an abnormal karyotype would be more important than the specific cytogenetic abnormality. Further research is required to identify the molecular lesions confemng the poor prognosis of patients with "unfavorable" karyotypes. New treatment modalities should be explored for patients with these "unfavorable" karyotypes who are largely resistant even to current autotransplant regimens.
